ARQT Arcutis Biotherapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$21.47

Period return

-7.96 (-27.05%)

Volume

1.6M

2026-06-01O $21.2 H $21.52 L $20.91 C $21.47MA5 $21.33MA20 $21.4MA60 $22.72MA120 $25.02

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 07.LowBUY26 days ago
Needham: Buy
US analyst rating / recommendation change.
2026. 03. 02.LowBUY3 months ago
Mizuho: Outperform
US analyst rating / recommendation change.
2026. 02. 28.LowBUY3 months ago
Guggenheim: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $34.63 · 8 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Westlake Village, CA, United States
Fiscal year end: —
Employees: 354
IPO date: —

View details →